NCT02784106已完成2 期
Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects With Rheumatoid Arthritis on Stable Methotrexate Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 2
- 主要终点
- Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response
研究概览
简要总结
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women 18 to 75 years of age at the time of informed consent signature
- •Confirmed diagnosis of RA according to 2010 American College of Rheumatology (ACR)/The European League Against Rheumatism (EULAR) RA classification criteria of at least 6 months duration
- •Positive RF and/or anti-CCP (anti-cyclic citrullinated peptide)
- •Persistently active disease defined as greater than equal to (>=) 6 swollen joints (of 66 counted) and >= 6 tender joints (of 68 counted)
- •High-sensitivity C-reactive protein (hsCRP) >= 3.6 milligram per liter (mg/L)
- •Treatment for >= 12 weeks with 10 to 25 mg/week MTX at a stable dose for at least 4 weeks prior to dosing with the investigational medicinal product (IMP) and maintained throughout the trial
- •Women of childbearing potential must use acceptable methods of contraception for 4 weeks prior to randomization, throughout the trial, and for 90 days after the last dose of IMP. For the purposes of this trial
- •Females who are postmenopausal (age-related amenorrhea >= 12 consecutive months and increased follicle-stimulating hormone [FSH] greater than (>) 40 milli international units per milliliter [mIU/mL]), or who have undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy testing. If necessary to confirm postmenopausal status, an FSH will be drawn at Screening
- •Acceptable contraception is defined as use of either 2 barrier methods (eg, female diaphragm and male condom), or 1 barrier method in conjunction with one of the following: spermicide, an intrauterine device, or hormonal contraceptives (implant or oral)
- •Women of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at Day 1/randomization before dosing.
排除标准
- •Use of oral corticosteroids > 10 mg daily prednisone equivalent, use of injectable corticosteroids, or change in dose of corticosteroids within 2 weeks prior to Screening or during Screening
- •Initiation or change in dose for nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to Screening
- •Treatment with tofacitinib, other Bruton's Tyrosine Kinase (BTK) inhibitors, or a biologic disease-modifying antirheumatic drug (DMARD; eg, anti-tumor necrosis factor alpha [anti-TNF-α], tocilizumab [anti-interleukin-6 receptor], abatacept [CTLA4-Fc]), or other immunosuppressive drugs(sulfasalazine would be acceptable at a stable dose) other than methotrexate within 3 months prior to Screening or during Screening
- •Treatment with anti-CD20 therapy (eg, rituximab) within 12 months prior to Screening or during Screening
- •Immunologic disorder other than Rheumatoid Arthritis (RA), with the exception of secondary Sjogren's syndrome associated with RA, and well-controlled diabetes or thyroid disorder, or any other condition requiring oral, intravenous, intramuscular, or intra-articular corticosteroid therapy
- •Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- •Active, clinically significant, viral, bacterial, or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks of Screening or during Screening, or completion of oral anti-infectives within 2 weeks before or during Screening, or a history of recurrent infections (ie, 3 or more of the same type of infection in a 12-month rolling period). Vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus considered by the Investigator to be sufficiently controlled would not be exclusionary
- •History of or positive testing for human immunodeficiency virus (HIV), hepatitis C antibody and/or polymerase chain reaction, hepatitis B surface antigen (HBsAg) (+) and/or hepatitis B core total, and/or IgM antibody (+) at Screening
- •History of or current diagnosis of active tuberculosis (TB); undergoing treatment for latent TB infection (LTBI); untreated LTBI (as determined by documented results within 3 months of the Screening Visit of a positive TB skin test with purified protein derivative with induration >= 5 millimeter (mm), a positive QuantiFERON-TB test or positive or borderline T-SPOT [Elispot] test); or positive QuantiFERON-TB test at Screening. Participants with documented completed appropriate LTBI treatment would not be excluded and are not required to be tested
- •Participants with current household contacts with active TB will also be excluded
- •Indeterminate QuantiFERON-TB or T-SPOT tests may be repeated once, and will be considered positive if retest results are positive or indeterminate
- •History of cancer, except adequately treated basal cell or squamous cell carcinomas of the skin (no more than 3 lesions requiring treatment in lifetime) or carcinoma in situ/cervical intraepithelial neoplasia of the uterine cervix, unless considered cured > 5 years
- •Clinically significant abnormality on electrocardiogram (ECG), or an active infective process or any other clinically significant abnormality on Screening chest X-ray (CXR) taken within 4 weeks of the first dose, per Investigator opinion. If a CXR has been taken within the previous 3 months and results are available and normal, the CXR does not need to be carried out
- •B cell (CD19) count less than (<) 50% of the lower limit of normal at Screening
- •Significant cytopenia including absolute neutrophil count < 1,500/ mm^3, platelet count < 100,000/mm^3, or absolute lymphocyte count < 1,000/mm^3
研究组 & 干预措施
M2951/M2951: Open Label Extension Period
Experimental
干预措施: M2951 (Drug)
Placebo: Double-Blind Treatment Period
Placebo Comparator
干预措施: Placebo (Drug)
M2951: Double-Blind Treatment Period
Experimental
干预措施: M2951 (Drug)
Placebo/M2951: Open Label Extension Period
Experimental
干预措施: M2951 (Drug)
结局指标
主要结局
Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response
时间窗: Day 84
ACR 20 response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Proportion of ACR20 responders = Number of participants with ACR20 response divided by total participants.
次要结局
- Absolute Immunoglobulin Levels at Day 85(Baseline, Day 85)
- Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 84(Baseline, Day 84)
- Change From Baseline in Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody Levels at Day 28 and 84(Baseline, Day 28 and Day 84)
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(Baseline up to 16 Weeks)
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity(Baseline up to 16 Weeks)
- Plasma Concentration of M2951(Pre-dose at Day 1; 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29)
- Maximum Observed Plasma Concentration (Cmax) of M2951(Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29)
- Plasma Concentration Observed Immediately Before Dosing on Day 29 (Cpre) of M2951(Pre-dose on Day 29)
- Time to Reach Maximum Plasma Concentration (Tmax) of M2951(Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29)
- Accumulation Ratio for Area Under the Concentration-Time Curve From Time Zero to 6 Hours (Racc [AUC0-6h]) of M2951(Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29)
- Proportion of Participants Achieving American College of Rheumatology-50 (ACR50) Response(Day 28, Day 56 and Day 84)
- Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Day 28 and 84(Baseline, Day 28 and Day 84)
- Change From Baseline in Rheumatoid Factor (RF) at Day 28 and 84(Baseline, Day 28 and Day 84)
- Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 28(Baseline, Day 28)
- Proportion of Participants Achieving American College of Rheumatology-70 (ACR70) Response(Day 28, Day 56 and Day 84)
- Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 3.2(Day 84)
- Change From Baseline in Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Day 84(Baseline, Day 84)
- Accumulation Ratio for Observed Maximum Plasma Concentration (Racc [Cmax]) of M2951(Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29)
- Absolute Change From Baseline in Immunoglobulin Levels at Day 85(Baseline, Day 85)
- Absolute B-Cell Levels at Day 85(Day 85)
- Absolute Change From Baseline in B-cell Levels at Day 85(Baseline, Day 85)
- Mean Change From Baseline in Disease Activity Score Based on a 28 Joint Count High-Sensitivity C-Reactive Protein (DAS28-hsCRP) at Day 28 and 84(Baseline, Day 28 and Day 84)
- Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 2.6(Day 84)
- Change From Baseline in Self-assessment of Pain Based on Visual Analog Scale (VAS) Score at Day 84(Baseline, Day 84)
- Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Day 84(Baseline, Day 84)
- Number of Participants With Grade 3 or Higher Clinically Significant Abnormality for Hematology, Biochemistry, Urinalysis or Coagulation(Baseline up to 16 Weeks)
- Area Under the Concentration-Time Curve From Time Zero to 6 Hours (AUC 0-6h) of M2951(Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29)
- Change From Baseline in Self-assessment of Disability Using Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Day 84(Baseline, Day 84)
- Number of Participants With Clinically Significant Vital Signs Abnormalities(Baseline up to 16 Weeks)
- Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings(Baseline up to 16 Weeks)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
A Phase II Study of M2951 in SLESystemic Lupus ErythematosusNCT02975336EMD Serono Research & Development Institute, Inc.469
撤回
2 期
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia GravisGeneralized Myasthenia GravisNCT04982289Alexion Pharmaceuticals, Inc.
进行中（未招募）
2 期
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent VaccineCondylomata AcuminataNCT02710851Jun Zhang640
已完成
2 期
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisPsoriasis VulgarisNCT00287547Bristol-Myers Squibb144
已完成
2 期
Safety and Efficacy Study of CF101 to Treat PsoriasisPlaque PsoriasisNCT00428974Can-Fite BioPharma76